Assembly Biosciences, Inc - ASMB STOCK NEWS

Assembly Bio announces the discontinuation of clinical development for vebicorvir (VBR), its first-generation core inhibitor, based on ineffective interim efficacy data from ongoing trials. The focus will shift to next-generation core inhibitors ABI-H3733 and ABI-4334, which have shown significantly higher potency in preclinical studies. The company will undergo organizational restructuring, reducing its workforce by approximately 30%, thus extending its cash runway into the first half of 2024. Initial data from the ABI-H3733 trial is expected in H2 2022.

Assembly Biosciences (Nasdaq: ASMB) reported promising advancements in its investigational HBV core inhibitor programs ABI-H3733, ABI-4334, and vebicorvir (VBR) during the International Liver Congress 2022.

Key data highlights include:

• ABI-H3733 shows improved pharmacokinetics in a new tablet formulation.
• ABI-4334 demonstrates significant potency against HBV cccDNA formation.
• VBR, under Phase 2 studies, exhibits enhanced antiviral effects when combined with entecavir.

Assembly aims to deliver innovative therapies for the 296 million people affected by HBV worldwide.

Assembly Biosciences (ASMB) has announced a new research program focusing on a novel oral interferon-α receptor agonist, aimed at enhancing treatment for hepatitis B. This program will leverage the antiviral mechanisms of interferon-α while minimizing systemic exposure, potentially improving patient tolerability. A live webcast is scheduled for July 26, 2022, featuring key speakers including Professor Edward J. Gane and CEO John McHutchison. The company remains committed to developing curative therapies for the 296 million individuals affected by HBV globally.

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology firm, announced the acceptance of six abstracts for presentation at the International Liver Congress™ 2022 held from June 22-26. The data covers investigational core inhibitors including vebicorvir and two new candidates, ABI-H3733 and ABI-4334. CEO John McHutchison emphasized the significance of the presentations, which support the company's goal of developing finite therapies for hepatitis B virus (HBV). The posters will be accessible online for conference registrants, showcasing new insights into their drug candidates.

Assembly Biosciences, Inc. (Nasdaq: ASMB) has initiated a Phase 1b trial for its next-generation core inhibitor, ABI-H3733, targeting chronic hepatitis B virus (cHBV) infection. This trial follows a successful Phase 1a study that showed a favorable safety profile and assesses a new tablet formulation designed for once-daily dosing. Approximately 50 treatment-naïve patients will participate in a 28-day, randomized, double-blind study to evaluate the drug's safety and antiviral activity, with results supporting future Phase 2 trial dose selection.

Assembly Biosciences, Inc. (Nasdaq: ASMB) announced a grant of stock options for 16,000 shares to a new employee at an exercise price of $1.87 per share. The options will vest over four years and were given as a material inducement for employment. This grant aligns with the company’s 2017 Inducement Award Plan and adheres to Nasdaq Listing Rule 5635(c)(4). Assembly Bio specializes in innovative therapeutics for hepatitis B virus (HBV), aiming to provide curative treatments for the 296 million people affected globally.

Assembly Biosciences (ASMB) reported its financial results for Q1 2022, highlighting a cash position of $146.5 million, down from $174.6 million at year-end 2021, expected to fund operations into Q4 2023. The company introduced a new small molecule entry inhibitor targeting HBV and HDV, expanding its pipeline. Research and development expenses decreased to $17.2 million from $18.6 million year-over-year, while general and administrative costs also fell to $6.0 million. Net loss narrowed to $23.1 million ($0.48 per share) from $27.2 million ($0.69 per share) in Q1 2021.

Assembly Biosciences (ASMB), a clinical-stage biotech company, announced the granting of stock options to a new employee for 19,000 shares at an exercise price of $2.06, the closing price on April 1, 2022. The stock options will vest over four years, with the first quarter vesting after one year. This grant is part of Assembly Bio's 2017 Inducement Award Plan and was approved by the independent Compensation Committee. Assembly Bio focuses on developing therapies for hepatitis B virus and aims to provide curative treatments for the 296 million affected individuals worldwide.

Assembly Biosciences announces the addition of Professor Michael P. Manns, MD, to its leadership team, focusing on hepatitis B and delta viruses. A webcast is scheduled for March 31, 2022, to unveil a new research program targeting HBV and HDV via an innovative orally bioavailable small-molecule approach. Key speakers include Manns, Assembly Bio CEO John McHutchison, and Chief Scientific Officer William Delaney. The company aims to advance therapies for the 296 million individuals with HBV globally, emphasizing the urgent need for treatment options.